Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Should You Buy BioMarin Pharmaceutical Before Feb. 18?

Summary by The Motley Fool
Key PointsBioMarin expects strong sales for its rare-disease drug, Voxzogo, in Q4.The company also has several important catalysts on the way in the first half of the year.However, uncertainty about competition for Voxzogo could be enough to keep investors on the sideline for now.10 stocks we like better than BioMarin Pharmaceutical › BioMarin Pharmaceutical's (NASDAQ: BMRN) website doesn't show any scheduled events on its calendar over the next…

1 Articles

The Motley FoolThe Motley Fool
Lean Left

Should You Buy BioMarin Pharmaceutical Before Feb. 18?

Key PointsBioMarin expects strong sales for its rare-disease drug, Voxzogo, in Q4.The company also has several important catalysts on the way in the first half of the year.However, uncertainty about competition for Voxzogo could be enough to keep investors on the sideline for now.10 stocks we like better than BioMarin Pharmaceutical › BioMarin Pharmaceutical's (NASDAQ: BMRN) website doesn't show any scheduled events on its calendar over the next…

·Alexandria, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Motley Fool broke the news in Alexandria, United States on Saturday, January 31, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

San Rafael icon

San Rafael

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal